促红细胞生成素刺激剂在芦可替尼治疗的骨髓纤维化患者贫血管理中安全有效
该研究纳入59例接受芦可替尼治疗的贫血性骨髓纤维化患者,其中93%为DIPSS中危-2/高危,52.5%依赖输血。促红细胞生成素刺激剂(ESA)联合芦可替尼的贫血缓解率为54%,5年时76%的患者有缓解;内源性促红细胞生成素<125 U/L与更高的贫血缓解率相关(63% vs 20%,P=0.008),未发生血栓事件或其他毒性。
要点
- ESA联合芦可替尼治疗骨髓纤维化贫血的缓解率为54%,5年时76%患者有缓解。
- 内源性促红细胞生成素<125 U/L者贫血缓解率更高(63% vs 20%,P=0.008)。
- 未发生血栓事件或其他毒性,4年总生存率为62%。
核心结论
- ESA在芦可替尼治疗的骨髓纤维化患者中似乎能有效改善贫血。
研究设计与样本
- 研究纳入59例接受芦可替尼治疗的贫血性骨髓纤维化患者,其中93%为DIPSS中危-2/高危,52.5%依赖输血。
主要发现
- 贫血缓解率为54%,76%的患者在5年时有缓解。
- 另有15%的患者贫血轻度改善,78%的患者脾脏缩小。
- 内源性促红细胞生成素<125 U/L与更高的贫血缓解率相关(63% vs 20%,P=0.008)。
- 未发生血栓事件或其他毒性。
- 4年总生存率为62%,受DIPSS和输血依赖影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Erythropoiesis-stimulating agents (ESAs) were combined with ruxolitinib in 59 anaemic myelofibrosis patients (93% with Dynamic International Prognostic Scoring System [DIPSS] intermediate-2/high risk; 52·5% transfusion-dependent). Anaemia response (AR) rate was 54% and 76% of patients responded at 5 years. A further 15% displayed minor improvement in anaemia and 78% of patients reduced spleen size. Endogenous erythropoietin levels <125 u/l correlated with a higher AR rate (63% vs. 20%, P = 0·008). No thrombotic events or other toxicities occurred. Overall survival was 62% at 4 years, influenced by DIPSS and transfusion dependency. ESAs seem effective in improving anaemia in ruxruxolitinib-treated myelofibrosis patients.
引用
- Crisà E, Cilloni D, Elli EM, et al. The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2018. PMID: 29984826. doi:10.1111/bjh.15450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。